Aorfix aneurysm graft CE mark expected soon
This article was originally published in Clinica
Lombard Medical Technologies hopes to gain expanded CE mark approval for Aorfix, its endovascular stent graft, in the first half of 2009. The expanded indication will enable the device, which treats abdominal aortic aneurysms (AAAs), to be used in patients with high-angle-neck aneurysms. The Didcot, UK company expects that the use of Aorfix to treat patients with aneurysm neck-angulations of up to 90 degrees will accelerate sales in Europe. Lombard is also concentrating on the US market, with patient recruitment into a pivotal US trial of Aorfix due in the second quarter of 2009; over 70% of the trial's intended 160 patients have so far been enrolled.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.